N@N

Derma Sciences Announces Third Quarter 2010 Results Conference Call

^{Published on 2010-11-05 19:01:25 - Market Wire}
 

PRINCETON, N.J.--([ BUSINESS WIRE ])--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, will hold a conference call on November 12, 2010 to discuss the financial results for the third quarter ended September 30, 2010. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

The conference call is scheduled to begin at 11:00 a.m. EST (Eastern Standard Time). The results will be released before the opening of the market that same day.

To access the conference call, U.S.-based listeners should dial (888) 563-6275 and international listeners should dial (706) 634-7417. All listeners should provide the following passcode: 23392989.

Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Companya™s website, [ www.dermasciences.com ]. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast.

Following the end of the conference call, a replay will be available through November 14, 2010, and can be accessed by dialing (800) 642-1687 within the U.S. or (706) 645-9291 outside of the U.S. All listeners should provide the following passcode: 23392989. The webcast will also be available for 30 days.

About Derma Sciences, Inc.

Derma Sciences is a medical technology company focused on three segments of the wound care marketplace, traditional dressings, advanced wound care dressings and pharmaceutical wound care products. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 patients with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudates, and BIOGUARD® for infection prevention. As noted above, Derma Sciences expects to complete the efficacy portion of its Phase 2 clinical study with DSC127, a novel pharmaceutical for accelerated wound healing and scar reduction, by the end of 2010.

For more information please visit [ www.dermasciences.com ].